日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Circulating miRNA markers show promise as new prognosticators for multiple myeloma

循环 miRNA 标志物有望成为多发性骨髓瘤的新预后指标

Rocci, A; Hofmeister, C C; Geyer, S; Stiff, A; Gambella, M; Cascione, L; Guan, J; Benson, D M; Efebera, Y A; Talabere, T; Dirisala, V; Smith, E M; Omedè, P; Isaia, G; De Luca, L; Rossi, D; Gentili, S; Uccello, G; Consiglio, J; Ria, R; Benevolo, G; Bringhen, S; Callea, V; Weiss, B; Ferro, A; Magarotto, V; Alder, H; Byrd, J C; Boccadoro, M; Marcucci, G; Palumbo, A; Pichiorri, F

CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma

CS1特异性嵌合抗原受体(CAR)工程化自然杀伤细胞增强了体外和体内抗人多发性骨髓瘤的抗肿瘤活性

Chu, J; Deng, Y; Benson, D M; He, S; Hughes, T; Zhang, J; Peng, Y; Mao, H; Yi, L; Ghoshal, K; He, X; Devine, S M; Zhang, X; Caligiuri, M A; Hofmeister, C C; Yu, J

Phase I ficlatuzumab monotherapy or with erlotinib for refractory advanced solid tumours and multiple myeloma.

ficlatuzumab 单药治疗或与厄洛替尼联合治疗难治性晚期实体瘤和多发性骨髓瘤的 I 期临床试验

Patnaik A, Weiss G J, Papadopoulos K P, Hofmeister C C, Tibes R, Tolcher A, Isaacs R, Jac J, Han M, Payumo F C, Cotreau M M, Ramanathan R K

The hematopoietic stem cell transplant comorbidity index can predict for 30-day readmission following autologous stem cell transplant for lymphoma and multiple myeloma

造血干细胞移植合并症指数可以预测淋巴瘤和多发性骨髓瘤自体干细胞移植后30天内的再入院情况。

Jaglowski, S M; Ruppert, A S; Hofmeister, C C; Elder, P; Blum, W; Klisovic, R; Vasu, S; Penza, S; Efebera, Y A; Benson, D M Jr; Devine, S M; Andritsos, L A